Search
Advertisement
Pharma Stocks: Why Diagnostics Could Be The Next Healthcare Investment Opportunity

Pharma Stocks: Why Diagnostics Could Be The Next Healthcare Investment Opportunity

Sakshi Batra
Sakshi Batra
  • New Delhi,
  • Nov 17, 2026,
  • Updated Nov 17, 2026, 2:05 PM IST

India's pharma sector has outperformed the broader market, but are more gains ahead? Sunny Agrawal, DVP, Head of Fundamental Desk, SBI Securities, shares his outlook on pharma, healthcare and diagnostics stocks. He highlights the strong performance of CDMO companies such as Laurus Labs, Syngene and Anthem Biosciences, while pointing to diagnostics as a segment with further upside potential. Despite recent consolidation, companies such as Metropolis Healthcare and Thyrocare could see a catch-up rally over the next three to six months. The discussion also examines US pricing trends, generic drug opportunities and the evolving healthcare investment landscape.